Since listing in 1994, CSL Limited (ASX: CSL) has become a household name among Australian investors.
The biotech giant has had a strong track record of performing consistently well, regardless of market conditions.
However, following an initial surge during the height of the COVID-19 pandemic, the CSL share price has struggled. This, despite the overall Australian share market enjoying a strong recovery.
How has CSL performed?
In mid-February, CSL reported a strong set of results for the 6 months ended 31 December. The company reported a 16.9% increase in revenue of US$5,739 million and 44% growth in net profit after tax (NPAT).
CSL noted that the COVID-19 pandemic had influenced the performance of its Behring and Seqirus…